News Releases

Mar 14, 2022
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
Corporate
Mar 11, 2022
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
Products
Mar 08, 2022
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
Corporate
Mar 02, 2022
Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
Corporate
Feb 24, 2022
Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
Financial
Feb 23, 2022
New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test
Products
Feb 16, 2022
Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022
Corporate
Feb 14, 2022
Myriad Genetics to Present at Two Upcoming Healthcare Conferences
Corporate
Jan 05, 2022
Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference
Corporate
Jan 04, 2022
Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service
Corporate
Dec 15, 2021
New Year’s Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide Survey
Products
Dec 14, 2021
Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer
Corporate
Nov 23, 2021
The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults
Products
Nov 22, 2021
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment
Pipeline
Nov 02, 2021
Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans
Financial